Torsdag 1 Oktober | 14:39:11 Europe / Stockholm
Svenska | English
Kursutveckling under dagen för detta pressmeddelande (SEK).
Likviditet under dagen för detta pressmeddelande
Est. tid*
2027-02-23 08:00 Bokslutskommuniké 2026
2026-11-11 08:00 Kvartalsrapport 2026-Q3
2026-08-26 - Kvartalsrapport 2026-Q2
2026-05-15 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2026-05-05 - Kvartalsrapport 2026-Q1
2026-02-26 - Bokslutskommuniké 2025
2025-11-11 - Kvartalsrapport 2025-Q3
2025-08-26 - Kvartalsrapport 2025-Q2
2025-07-02 - Extra Bolagsstämma 2025
2025-05-15 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2025-05-14 - Årsstämma
2025-05-05 - Kvartalsrapport 2025-Q1
2025-02-27 - Bokslutskommuniké 2024
2024-11-11 - Kvartalsrapport 2024-Q3
2024-08-26 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2024-05-14 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-04-25 - Extra Bolagsstämma 2023
2024-02-27 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-19 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2023-05-17 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-24 - Bokslutskommuniké 2022
2022-11-29 - Extra Bolagsstämma 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2022-05-17 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-18 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2021-05-17 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-26 - Bokslutskommuniké 2020
2020-11-17 - Kvartalsrapport 2020-Q3
2020-08-25 - Kvartalsrapport 2020-Q2
2020-05-22 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2020-05-20 - Årsstämma
2020-04-29 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-15 - Kvartalsrapport 2019-Q3
2019-08-31 - Kvartalsrapport 2019-Q2
2019-05-23 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2019-05-22 - Årsstämma
2019-05-01 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
AlzeCure Pharma är ett läkemedelsbolag som forskar och utvecklar småmolekylära läkemedelskandidater för behandling av sjukdomar i det centrala nervsystemet, med särskilt fokus på Alzheimer och kronisk smärta. Bolaget utvecklar flera parallella projekt där teknologin och forskningen utgår ifrån egen läkemedelsplattform. AlzeCure Pharma har sitt huvudkontor i Huddinge, Sverige.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

AlzeCure Pharma to present at Swiss Nordic Bio 2026 in Zurich

2026-09-22 10:00:00

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer’s disease and pain, today announced that the company will participate and present at Swiss Nordic Bio 2026 in Zurich on October 1, a partnering and investor conference connecting Nordic, Swiss and Austrian companies in biotech, medtech and pharma with global investors and industry representatives.

At the event, CEO Martin Jönsson will give an updated view of the company following the recently signed collaboration and outlicensing agreements with US-based Eli Lilly and Denmark-based QuantumCell ApS, both relating to AlzeCure's Alzheimer's programs, and hold one-on-one meetings with investors and potential partners.

Date: October 1, 2026
Location: Zurich, Switzerland

Organizers: Business Sweden and Pareto Securities, in cooperation with Swiss and Austrian partners

The Swiss Nordic Bio conference gathers around 200 participants, including more than 70 investors, and features more than 40 company presentations as well as over 400 one-on-one partnering meetings.

For more information, please contact

Martin Jönsson, CEO
Tel: +46(0)70 786 94 43
martin.jonsson@alzecurepharma.com

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish biotech company developing new, innovative drug therapies for severe diseases and conditions affecting the central nervous system, such as Alzheimer’s disease and pain – indications where available treatment options today are very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several drug candidates in parallel based on three research platforms: NeuroRestore®, Alzstatin® and Painless. AlzeCure has recently signed collaboration and outlicensing agreements with Eli Lilly on the Alzstatin platform, and with QuantumCell ApS on the NeuroRestore platform.

FNCA Sweden AB is the company’s Certified Adviser. For more information, visit www.alzecurepharma.com

Image Attachments

Martin Jönsson CEO AlzeCure Pharma

Attachments

AlzeCure Pharma to present at Swiss Nordic Bio 2026 in Zurich

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Företag
Pressmeddelanden